Fore Capital’s Teva Pharmaceuticals TEVA Stock Holding History

Fore Capital’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-20,000	Closed	-$379K	–	87
2017 Q4	$379K	Buy	+20,000	New	+$301K	0.15%	62

Other funds holding TEVA

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Berkshire Hathaway Omaha, Nebraska $299B AUM 27.55% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACM

Abrams Capital Management Boston, Massachusetts $5.48B AUM 3.63% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fore Capital's TEVA Position: Q1 2018 in Review

Fore Capital sold out of Teva Pharmaceuticals (TEVA) in Q1 2018, closing a stake of 20,000 shares — an estimated $379K sold.

Fore Capital first reported a position in TEVA in Q4 2017 and held it in 1 quarter. The position peaked at $379K in Q4 2017. 507 funds tracked by Wall St. Rank hold TEVA as of Q1 2018.

Fore Capital reported no remaining Teva Pharmaceuticals position as of Q1 2018 after selling out during the quarter.
Fore Capital sold 20,000 Teva Pharmaceuticals shares in Q1 2018, an estimated $379K.
Fore Capital first reported a position in Teva Pharmaceuticals in Q4 2017 and held it in 1 quarter.
Fore Capital's Teva Pharmaceuticals position peaked at $379K in Q4 2017.
507 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2018.

Based on Fore Capital's 13F filing for Q1 2018, filed 15 May 2018.